- Home
- GENK vs RNXT Comparison
GENK vs RNXT Comparison
Compare GENK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | RNXT |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 37.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GENK | RNXT |
|---|---|---|
| Price | $1.77 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.67 | ★ $8.00 |
| AVG Volume (30 Days) | 28.8K | ★ 256.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ 62.50 | 59.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,380,000.00 | $43,000.00 |
| Revenue This Year | $8.46 | $2,995.35 |
| Revenue Next Year | $8.17 | $219.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $0.70 |
| 52 Week High | $6.50 | $1.45 |
Technical Indicators
Market Signals| Indicator | GENK | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 59.83 |
| Support Level | $1.66 | $0.78 |
| Resistance Level | $2.55 | $1.07 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 48.62 | 75.68 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.